The aim of this randomised, controlled trial was to determine the optimum dose of fentanyl in combination with propofol 2.5 mg.kg -1 when inserting the Classic™ Laryngeal Mask Airway.
Since the introduction of the Classic™ Laryngeal Mask Airway (cLMA, Intravent Orthofix, Maidenhead, UK) in 1983 1 , it has gained widespread popularity and has been used extensively as an airway device during general anaesthesia 2 . However, a certain degree of jaw relaxation and depth of anaesthesia is required to insert the cLMA in a nonparalysed patient. Inadequate depth of anaesthesia can lead to coughing, bucking, gagging and laryngospasm 3 . Propofol is one of the most useful induction drugs for insertion of the cLMA, because of its superior relaxation of the jaw and suppression of airway reflexes 4, 5 , although adjuvants may be needed in many cases. Most anaesthesiologists would add an opioid to the induction dose of propofol to improve the conditions for insertion.
Alfentanil has been studied to determine the optimal dose as an adjunct to propofol for the insertion of the cLMA 6 . However, there are few data concerning the optimal dose of fentanyl for cLMA insertion. Therefore, we conducted this study to determine the optimum dose of fentanyl in combination with propofol 2.5 mg.kg -1 for cLMA insertion. The optimum dose was considered to be the dose that provided optimal insertion conditions, as determined using a three-point, six-category scale, as used in previous studies [6] [7] [8] .
MATERIALS AND METHODS
After obtaining approval from the Ethics Committee of University Malaya Medical Centre, we studied 75 ASA physical status I or II patients, aged 18 to 60 years undergoing elective minor surgery. All patients gave written informed consent. Patients were excluded from the study if they had any pathology of the neck, upper respiratory or upper alimentary tract, if they were at risk of pulmonary aspiration of gastric contents, if they had anticipated difficult airway or body mass index more than 30 kg.m -2 .
After enrolment, patients were randomly assigned to one of five groups (n=15 per group) by drawing of shuffled coded sealed envelopes: 0 µg.kg -1 (placebo), 0.5 µg.kg -1 , 1.0 µg.kg -1 , 1.5 µg.kg -1 and 2.0 µg.kg -1 fentanyl. The study drug was prepared and administered by an independent anaesthesiologist who was not involved with patient assessments. The study drug was drawn up into a syringe and diluted with normal saline to 5 ml.
All patients fasted for at least six hours. no premedication was given. All patients were monitored using continuous electrocardiography and pulse oximetry, and non-invasive arterial blood pressure measurement, cycled every one minute during the study period.
Patients' heads were supported on a firm silicone headrest and were kept in a neutral position. After pre-oxygenation for three minutes, anaesthesia was induced by first injecting the study drug rapidly over 10 seconds. Three minutes after the study drug was injected, propofol 2.5 mg.kg -1 was injected over 10 seconds. All drugs were administered into a free-running intravenous infusion. The cLMA was inserted four minutes and 30 seconds after injection of the study drug. A single anaesthesiologist (ASBT, who had used the cLMA more than 500 times), who was unaware of the group to which the patient had been assigned, inserted the cLMA in all cases. The cLMA was inserted according to the manufacturer's instructions. The dosage was also concealed from the main investigator (CYW) who assessed the cLMA insertion conditions. After insertion, an initial assessment of ventilation was made after the device had been connected to the breathing system by either observing the patient's respiratory movement and the capnogram when breathing spontaneously or, in apnoeic patients (most cases), observing for chest expansion and the capnogram by gently squeezing the reservoir bag. When the cLMA was found to be obstructed, due to faulty placement or prolonged laryngospasm, it was removed and another dose of propofol (1 mg.kg -1 ) was given, followed by another attempt at cLMA insertion made 60 seconds later. A failed attempt was defined as removal of the cLMA from the mouth. A maximum of three attempts was allowed and the number of attempts was recorded. After three failed attempts, the patient was to be withdrawn from the study and the airway managed using an alternative method.
If the patients remained apnoeic for more than 30 seconds after LMA insertion, the lungs were manually ventilated to maintain an end-tidal CO 2 of 40 to 50 mmHg until spontaneous ventilation returned. Prolonged apnoea was defined as more than five minutes after insertion of the cLMA. After the cLMA had been successfully inserted, anaesthesia was maintained with 2.5% sevoflurane and 70% nitrous oxide in oxygen, and no further data were collected.
Patient details, apnoea (>5 minutes) and insertion conditions (described below) were recorded. Each patient's blood pressure and heart rate were recorded before induction, one minute after induction and one minute after cLMA insertion. The incidence of severe hypotension (systolic blood pressure <80 mmHg) and bradycardia (heart rate <50 bpm) were recorded. Insertion conditions were graded using a three-point, six-category scale (1 to 6), which has been used successfully in previous studies [6] [7] [8] .
resistance to mouth-opening grading: nil, mild, 1.
significant (undue force required). resistance to insertion grading: no, mild, 2.
significant (undue force required).
Swallowing grading: nil, mild or gross.
3.
Coughing and gagging grading: nil, mild or gross.
4.
Head or body movement grading: nil, mild or 5.
gross.
Laryngospasm grading: nil, partial or total. 6.
Each category was given a score of 1, 2 or 3 according to the severity.
The score for insertion was calculated by adding the grades for all the insertion conditions. The optimum fentanyl dose was that dose associated with a score of 1 for all the six insertion conditions.
The primary outcome was the percentage of patients with no response to LMA insertion (i.e. score=6). The sample size calculation was based on previous study by Wong et al 8 . The percentage of patients who responded to LMA insertion was 64% in their placebo group. To detect a reduction to 20%, 15 patients in each group were required to achieve 80% power with an [alpha] error of 0.05.
The chi-square test for trends 'linear association' was used to compare insertion conditions with respect to increasing dosage. The 5% level of probability (P <0.05) was taken as the criterion for significance. Statistical analysis was performed using SPSS (version 14.0; 2005, SPSS Inc., Chicago, IL, USA).
RESULTS
The total number of patients studied was 75. Patients' characteristics with respect to age, gender, weight and ASA physical status were similar across the five groups (Table 1) . no patient developed severe hypotension or bradycardia.
Successful cLMA insertion
The cLMA was successfully inserted on the first attempt in only one patient in the placebo group, compared to nine in the 0.5 µg.kg -1 group, 14 in the 1.0 µg.kg -1 group, 13 in the 1.5 µg.kg -1 group and 13 in 2.0 µg.kg -1 group (P <0.0001) ( Table 1) .
Optimum score in cLMA insertion
An optimal score for insertion was calculated by adding the grades for all the insertion condition categories of 1, 2 or 3. A total score of 6 would be considered optimal. However, in this study there was a very high proportion of patients who had some resistance to mouth-opening. Therefore, mouth-opening and ease of insertion were not included in the final score, but considered separately. As such, the optimal score was reduced to 4.
In the placebo group, no patient (0%) achieved an optimum score of 4 compared to six (40%) in the Prolonged apnoea (>5 min) 0 (0%) 0 (0%) 1(6.7%) 1 (6.7%) 9 (60%)
Optimum score (4) 0 (0%) 6 (40%) 12 (80%) 11 (73%) 12 (80%) (Table 1) .
Insertion conditions
The incidence of resistance to mouth-opening (P=0.041), resistance to insertion (P <0.0001), swallowing (P <0.0001), coughing and gagging (P <0.0001) and movement (P <0.0001) all decreased with increasing dose of fentanyl. There was one patient in the placebo group who had partial laryngospasm (P=0.399). no patient developed severe laryngospasm requiring tracheal intubation ( Table 2) .
Prolonged apnoea
The incidence of patients having prolonged apnoea increased with increasing dose of fentanyl (P <0.0001) ( Table 1 ).
DISCUSSION
In this study, we investigated the optimum dose for intravenous fentanyl as an adjunct to propofol 2.5 mg/kg for the insertion of the cLMA in nonparalysed patients. We used a methodology similar to that developed by previous researchers to assess insertion conditions 9,10 using a six-variable/threegrade score (Table 2) . However, in the present study there was a high incidence of some resistance to mouth-opening. This was also similar to other reported studies, which have shown that mouthopening and ease of insertion were influenced by anatomical features of the upper airway 8 . Another explanation for our findings is that the dose of propofol (2.5 mg.kg -1 ) used for the placement of cLMA in this study may not be adequate in young patients who are not premedicated. Tanaka and colleagues have recommended that without fentanyl, propofol 3.7 mg.kg -1 is required to achieve a satisfactory level of anaesthesia in most patients for LMA insertion 11 . Therefore, we altered our optimum insertion score and based it on only four categories of insertion conditions (swallowing, gagging or cough, movement and laryngospasm).
We found that higher doses of fentanyl are associated with high incidence of apnoea. We found that a significantly high incidence of apnoea occurred mainly in the 2 µg.kg -1 group. We also noted that all 14 of the 15 patients in the placebo group who had no apnoea had repeated attempts at LMA insertion, compared to two out of six patients in the 2 µg.kg -1 fentanyl group. We cannot exclude the possibility that this could have influenced the duration of apnoea in the placebo group. Prolonged apnoea is undesirable if spontaneous ventilation is planned or if the duration of surgery is short. Therefore, it is important to use a minimum effective dose.
We found that there was a high rate of successful first attempt at insertion with 1 µg.kg -1 and 1.5 µg.kg -1 , 93 and 87% respectively, compared to 87% in the 2.0 µg.kg -1 group. These differences were most likely due to inter-individual variability in responses to fentanyl 12 .
The 1.0 µg.kg -1 group also achieved an 80% optimal score of 4, compared to 73% in the 1.5 µg.kg -1 group and 80% in the 2 µg.kg -1 group (Table 1 ). This suggests that 1.0 µg.kg -1 adequately obtunded laryngeal reflex responses during the insertion of cLMA. Therefore, we recommend 1.0 µg.kg -1 as the optimal dose of fentanyl when used in addition to propofol 2.5 mg/kg for the insertion of the cLMA.
Other studies have investigated the use of fentanyl in reducing the dose of propofol required during insertion of cLMA. One study found that pretreatment with fentanyl reduced the effective target concentration of propofol required. However, it did not differentiate whether 1 µg.kg -1 or 2 µg.kg -1 fentanyl was used 13 . Another study reported that 2 µg.kg -1 of fentanyl reduced propofol requirement by 60%, but contributed significantly to prolonged apnoea 14 .
In a recent study by Wong et al 8 determining the fentanyl dose for inserting the cLMA, it was reported that a standard fentanyl dose of 1 µg.kg -1 , co-administered with propofol 2.5 mg.kg -1 , provided optimal conditions in 65% of cases. The difference in their results and ours might be accounted for by the differences in the time interval between the administration of fentanyl and cLMA insertion. In the Wong et al study, the insertion of cLMA was performed 90 seconds after administration of fentanyl. Whereas in our study, we prolonged the insertion time to four minutes 30 seconds before inserting the cLMA. This longer time interval was chosen because other studies have shown that the time at which peak effect site concentration with fentanyl occur ranges from three to six minutes 15, 16 . Another study has shown that the circulatory response will be attenuated three minutes after fentanyl injection, and at least five minutes was the optimal onset time for tracheal intubation 17 .
We found that there were no instances of severe hypotension or bradycardia with any of the doses of fentanyl. However, we studied only young, fit patients who were not premedicated. We cannot comment on the haemodynamic effects on patients with co-morbidities, at the extreme of ages or with the use of other adjuncts such as benzodiazepines.
In conclusion, our study demonstrated that the addition of fentanyl significantly improves the conditions for cLMA insertion. For optimal insertion conditions cLMA insertion conditions in healthy adults, when used in associated with propofol 2.5 mg.kg -1 , we recommend a fentanyl dose of 1.0 µg.kg -1 .
